Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of XXXX .

@entity1 @entity1165 @entity235 @entity1188 @entity2778
Eighteen @entity1 with sustained @entity1165 underwent serial electrophysiological studies to establish the therapeutic efficacy of @entity2778 as compared to other available anti-arrhythmic agents. One or more acutely effective drug was found in 14 of the 18 @entity1 (78%). @entity2778 was tested in all 18 @entity1 and was effective in 12 of them (67%). For assessment of the prophylactic efficacy of other anti-arrhythmic agents, an average of 3.5 additional studies per @entity1 were performed resulting in successful prevention of @entity1165 in a total of 10 of 63 (16%) additional trials. Nine @entity1 were placed on chronic oral therapy with @entity2778 . In these nine @entity1 long-term prophylaxis against @entity1165 was documented over a mean follow-up period of 9.6 months (range 2-18 months). The study suggests that @entity2778 can provide effective prophylaxis against @entity1165 in a significant proportion of @entity1 refractory to other available drugs and that this prophylactic efficacy is predominantly due to its Class III anti-arrhythmic properties. Experimental studies were performed in eight conscious @entity235 3-7 days following proximal LAD ligation. Epicardial recordings were obtained using implanted composite electrodes. @entity2778 prevented sustained VT by a predominant increase in refractoriness of the infarcted zone. In vitro, @entity2778 caused a significant prolongation of the action potential of @entity1188 . Refractoriness of epicardial ventricular fibres was significantly more prolonged in ischemically damaged cells as compared to normal fibres.
